Pharmaceutical News

RSS

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Scientists discover new anti-cancer and anti-metastatic molecule

A new molecule with anti-cancer and anti-metastatic properties has been discovered by teams from CNRS, CEA, the Institut Curie and Inserm, in collaboration with Australian and British researchers.

4 Sep 2012

Meijer offers generic Lipitor for free to help families be heart healthy

In an effort to help families be heart healthy, this week Midwest retailer Meijer began offering the generic substitute for Lipitor (atorvastatin calcium) for free in all 199 Meijer pharmacies.

4 Sep 2012

GE Healthcare introduces KUBio factory

GE Healthcare, the healthcare business of GE, today introduced KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

4 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

MDA7 compound shows promise against Alzheimer's disease

A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer's disease, according to a study by researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute.

3 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

Tandem Diabetes Care announces availability of t:slim Insulin Pump

Tandem Diabetes Care, Inc. announced today that it has started shipping the t:slim Insulin Pump to customers. The t:slim Insulin Pump is the only insulin pump with a touch screen approved by the U.S. Food and Drug Administration.

1 Sep 2012

Dysfunctional RyRs play a role in stress-induced cognitive dysfunction

ARMGO Pharma, Inc., a biopharmaceutical company developing innovative small molecule drugs known as "Rycals™," which act on the ryanodine receptor calcium-release channel (RyR), announced that a study published today in the prestigious scientific journal Cell reveals the underlying role of calcium leak through the RyR as an important contributor to stress-induced cognitive dysfunction.

1 Sep 2012

Researchers define new treatment for potentially fatal lung disease in patients with CVID

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).

1 Sep 2012

Mauritian official warns of counterfeit medicine dangers

Speaking Wednesday at a seminar titled "Campaign Against Counterfeit Medicines," Mauritian Health and Quality of Life Minister Lormus Bundhoo "cautioned against the dangers posed by counterfeit drugs and their impact on human life" and "said that the authorities are determined to raise awareness on the dangers of the manufacture of and trade in counterfeit medicines, and the importance of combating counterfeit medicines in Mauritius," PANA/Afriquejet reports.

31 Aug 2012

Research identifies new pathway to target with anti-inflammatory drugs

Scientists' discovery of an important step in the body's process for healing wounds may lead to a new way of treating inflammation.

31 Aug 2012

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

31 Aug 2012

Astellas Pharma adopts Advantest’s terahertz spectroscopic imaging system TAS7500

Advantest Corporation today announced that its terahertz spectroscopic imaging system TAS7500, which utilizes Advantest's THz wave technology, has been adopted by Astellas Pharma Inc.

31 Aug 2012

Non-pain-related factors predict long-term opioid use after surgery

Non-pain-related factors—including previous use of pain medications, high perceived risk of addiction, and symptoms of depression—increase the risk of continuing to use strong pain-relieving drugs several months after surgery, reports a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

31 Aug 2012